drugset / Trial / NCT01263951
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Phase 2
Unknown
35 enrolled
Thomas Jefferson University
Bayer · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
Timeline
- Start
- 2010-11
- Primary completion
- 2021-02-01
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Sorafenib | Small molecule | 200 mg | — |